Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.69 |
| ▸ | RAF1 | P04049 | 10/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379947 | 0.87 | RAF1 (0.66) | BRAFRAF1EGFR | |
| SCHEMBL16379930 | 0.87 | RAF1 (0.66) | BRAFRAF1EGFR | |
| SCHEMBL20310349 | 0.87 | RAF1 (0.66) | BRAFRAF1EGFR | |
| SCHEMBL16380632 | 0.87 | RAF1 (0.66) | BRAFRAF1EGFR | |
| SCHEMBL16380262 | 0.85 | BRAF (0.55) | BRAFRAF1EGFR | |
| SCHEMBL16380162 | 0.85 | BRAF (0.55) | BRAFRAF1EGFR | |
| SCHEMBL19237454 | 0.82 | BRAF (0.79) | BRAFRAF1EGFR | |
| SCHEMBL16380753 | 0.82 | BRAF (1.00) | BRAFRAF1EGFR | |
| SCHEMBL19242869 | 0.80 | BRAF (0.65) | BRAFRAF1EGFR | |
| SCHEMBL17800232 | 0.80 | RAF1 (0.78) | BRAFRAF1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2020-02-18 | — | — | US | disclosed |
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2019-02-19 | — | — | US | disclosed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| US-9920055-B2 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | BEIGENE, LTD. (KY) | 2018-03-20 | — | — | US | disclosed |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2017-08-17 | — | — | US | disclosed |
| WO-2014206343-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144446-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885EGFR 248/4885 |
| US-20170233391-A1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885EGFR 248/4885 |
| US-10208038-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885EGFR 248/4885 |
| US-10562899-B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885EGFR 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.